ArticleExpert opinion on drug safety
Underreporting of Adverse Drug Events: a Look into the Extent, Causes, and Potential Solutions.
Article in Expert opinion on drug safety. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Incidence of and Risk Factors for Repeat Adverse Drug Events: A Systematic Review.Journal of patient safety · 2026Pooled it
- Machine learning to predict adverse drug events based on electronic health records: a systematic review and meta-analysis.The Journal of international medical research · 2024Pooled it
- Retrospective analysis of preventable procedural adverse events (ICD-10 Y62-Y69) in the TriNetX network: a multiregional study before, during and after the COVID-19 pandemic.BMJ quality & safety · 2026Article
- Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study.Advances in therapy · 2026Article
- Article
- Barriers to Adverse Drug Reaction Reporting Among Physicians, Nurses, and Pharmacists: A Scoping Review Comparing High-Income Versus Low-/Middle-Income Countries.Healthcare (Basel, Switzerland) · 2026Review
- Knowledge, attitudes, practices towards medication errors and adverse drug reactions reporting among healthcare professionals in Dongola, Sudan: a cross-sectional study.Scientific reports · 2025Article
- Adverse Reactions by Radiopharmaceuticals: Retrospective Analysis of the Portuguese National Pharmacovigilance System.The Annals of pharmacotherapy · 2025Observational
- Consensus recommendations for the integration of critical care pharmacists on intensive care unit teams: Endorsed by the American Association of Critical-Care Nurses, American College of Clinical Pharmacy, American Society of Health-System Pharmacists, Institute for Safe Medication Practices, and Society of Critical Care Medicine.Journal of the American College of Clinical Pharmacy : JACCP · 2025Article
- The Role of Adverse Event Follow-Up in Advancing the Knowledge of Medicines and Vaccines Safety: A Scoping Review.Drug safety · 2025Article
- Safety and Effectiveness of Pravastatin in Korean Patients with Dyslipidemia Based on the Cardiovascular Risk Classification: Pooled Analysis of Four Observational Studies.Endocrinology and metabolism (Seoul, Korea) · 2025Observational
- Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.ESMO real world data and digital oncology · 2025Article
- Building functional and sustainable pharmacovigilance systems: an analysis of pharmacovigilance development across high-, middle- and low-income countries.Therapeutic advances in drug safety · 2025Article
- Adverse drug reaction signal detection via the long short-term memory model.Frontiers in pharmacology · 2025Article
- Descriptive analysis of the national drug adverse events (AEs) database in Lebanon.Journal of pharmaceutical policy and practice · 2025Article
- Pharmacovigilance in Australia: how do adverse event reports from clinicians contribute to medicine and vaccine safety?Australian prescriber · 2024Review
- Pharmacovigilance of Radiopharmaceuticals: Challenges and Opportunities.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2024Article
- Transformers and large language models in healthcare: A review.Artificial intelligence in medicine · 2024Review
- Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
37300402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.